PLx Pharma Inc. to Present at Oppenheimer & Co’s 32nd Annual Healthcare Conference on March 15, 2022

Rhea-AI Summary

PLx Pharma Inc. (NASDAQ: PLXP) announced its participation in the 32nd Annual Healthcare Conference hosted by Oppenheimer & Co. on March 15, 2022. The event will feature presentations by Natasha Giordano, President and CEO, and Rita O’Connor, CFO, at 3:20 p.m. ET. The presentations will be available via webcast, with an archive for 30 days. PLx Pharma focuses on its patented PLxGuard™ technology to enhance drug absorption and mitigate stomach injury risks associated with certain medications.

SPARTA, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE^®”), today announced that Natasha Giordano, President and CEO of PLx Pharma Inc. and Rita O’Connor, Chief Financial Officer & Head of Manufacturing & Supply Chain, will present on March 15, 2022, at Oppenheimer & Co’s 32^nd Annual Healthcare Conference, which will be a virtual event this year.

Oppenheimer & Co’s 32^nd Annual Healthcare Conference

Date	Tuesday, March 15, 2022
Time	3:20 p.m. ET
Webcast (live and replay)	https://wsw.com/webcast/oppenheimer20/plxp/2818872

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via PLx Pharma’s investor relations website at https://ir.plxpharma.com/events-presentations/events.

About VAZALORE
VAZALORE is an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. VAZALORE delivers aspirin differently from plain and enteric coated aspirin products. The special complex inside the capsule is designed for targeted release of aspirin, limiting its direct contact with the stomach. VAZALORE delivers fast, reliable absorption for pain relief plus the lifesaving benefits of aspirin. To learn more about VAZALORE, please visit www.vazalore.com.

About PLx Pharma Inc.
PLx Pharma Inc. is a commercial-stage drug delivery platform technology company focused on improving how and where active pharmaceutical ingredients (APIs) are absorbed in the gastrointestinal (GI) tract via its clinically validated and patent protected PLxGuard™ technology. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach injury associated with certain drugs. To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.

Contacts:
Janet M. Barth
Vice President, Investor Relations & Corporate Communications, PLx Pharma Inc.
(973) 409-6542
IR@PLxPharma.com

Lisa M. Wilson
Founder & President, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

FAQ

What is PLXP's participation in the Oppenheimer & Co. Healthcare Conference?

PLXP will present at the Oppenheimer & Co. 32nd Annual Healthcare Conference on March 15, 2022.

Who will represent PLxp at the Oppenheimer Healthcare Conference?

Natasha Giordano, President and CEO, and Rita O’Connor, CFO, will represent PLx Pharma.

What time is PLXP's presentation at the Healthcare Conference?

PLXP's presentation will take place at 3:20 p.m. ET on March 15, 2022.

Where can I watch PLXP's presentation?

The presentation will be available via a live webcast.

What is VAZALORE and its significance for PLXP?

VAZALORE is an FDA-approved liquid-filled aspirin capsule developed by PLXP, aimed at improving drug absorption and minimizing stomach injury.